Physician profile
Rajeev Prabakaran
NPI 1366618209
$3,794.67
in general payments reported to CMS, 2019-2025
21 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $237 · 2021: $645 · 2022: $830 · 2023: $579 · 2024: $602 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,008.14 | 2021-2022 | |
| Abbvie INC. | $689.56 | 2020-2025 | |
| Boston Scientific Corporation | $649.99 | 2019-2025 | Exalt Model D, Resolution 360 Ultra Clip, Captivator II |
| Janssen Biotech, INC. | $239.77 | 2020-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $183.98 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $172.95 | 2019-2025 | Eohilia |
| Aimmune Therapeutics, INC. | $159.29 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $125.48 | 2024 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $124.98 | 2019 | |
| Novo Nordisk INC | $105.21 | 2023-2025 | Ozempic, Rybelsus |
| Axonics, INC. | $97.52 | 2023 | Axonics |
| Janssen Pharmaceuticals, INC | $38.97 | 2024 | Xarelto |
| Braintree Laboratories, INC. | $35.70 | 2021-2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $23.92 | 2025 | Iqirvo |
| Bayer Healthcare Pharmaceuticals INC. | $23.61 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.89 | 2021 | |
| Scpharmaceuticals INC. | $20.64 | 2024 | |
| Amgen INC. | $20.11 | 2023 | Repatha |
| Acell, INC. | $18.34 | 2019 | |
| Ardelyx, INC. | $17.27 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Prabakaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.